A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation

BACKGROUND & AIMS: Human allogeneic liver-derived progenitor cells (HALPC, HepaStem®; Promethera Biosciences, Mont-Saint-Guibert, Belgium) are an advanced therapy medicinal product that could potentially alleviate systemic inflammation and ameliorate liver function in patients with acute-on-chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Nevens, Frederik, Gustot, Thierry, Laterre, Pierre-François, Lasser, Luc L., Haralampiev, Lyudmil E., Vargas, Victor, Lyubomirova, Desislava, Albillos, Agustin, Najimi, Mustapha, Michel, Sébastien, Stoykov, Ivaylo, Gordillo, Noelia, Vainilovich, Yelena, Barthel, Virginie, Clerget-Chossat, Nathalie, Sokal, Etienne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207211/
https://www.ncbi.nlm.nih.gov/pubmed/34169246
http://dx.doi.org/10.1016/j.jhepr.2021.100291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207211/
https://www.ncbi.nlm.nih.gov/pubmed/34169246
http://dx.doi.org/10.1016/j.jhepr.2021.100291

Ejemplares similares